TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06324604: Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Sponsor: Mozart Therapeutics Australia Pty Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,005,216

Rescue Site Savings

+$3,973,376

Unlock Full NCT06324604 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06324604 Rescue Dossier →